CatLane
Truist upgraded pain therapy developer Pacira BioSciences (NASDAQ:PCRX) to Hold from Sell on Thursday, noting that the company’s management is “more likely” to settle a patent litigation with generic drugmaker eVenus Pharmaceutical Laboratories.
The upgrade came after Pacira (NASDAQ: